Skip to search formSkip to main contentSkip to account menu

rasagiline

Known as: (R)-Indan-1-yl-prop-2-ynyl-amine, rasagiline [Chemical/Ingredient], RAS 
National Institutes of Health

Related topics

Related topics

12 relations

Narrower (6)

AGN 1135AzilectN-propargyl-1-aminoindan mesylateTVP 101

Broader (3)

IndansMonoamine Oxidase InhibitorsNeuroprotective Agents
Rasagiline Tartraterasagiline 1 MG Oral Tablet [Azilect]rasagiline mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Rasagiline prevents apoptosis induced by PK11195, a ligand of the outer membrane translocator protein (18 kDa), in SH-SY5Y cells through suppression of cytochrome c release from mitochondria
Rasagiline protects neuronal cells from cell death caused by various lines of insults. Its neuroprotective function is due to… 
Review
2012
Review
2012
From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
Alzheimer's disease (AD) is a multifactorial syndrome involving a complex array of different, while related, factors in its… 
Review
2011
Review
2011
Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?
Evidence from clinical trials with monoamine oxidase type B inhibitors (TEMPO, ADAGIO and DATATOP) and levodopa (ELLDOPA… 
Review
2007
Review
2007
Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?
Review
2007
Review
2007
Why hasn't neuroprotection worked in Parkinson's disease?
Despite encouraging preclinical results, clinical trials of neuroprotective agents for Parkinson's disease have failed to show… 
Review
2007
Review
2007
New strategies in motor parkinsonism.
Review
2006
Review
2006
Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?
Neuronal death in Parkinson's disease (PD) may originate from the reciprocal interactions of a restricted number of conditions… 
Review
2006
Review
2006
New pharmacologic horizons in the treatment of Parkinson disease
Many of the motoric features that define Parkinson’s disease (PD) result primarily from the loss of dopaminergic neurons of the… 
Highly Cited
2002
Highly Cited
2002
Early and Late Gene Changes in MPTP Mice Model of Parkinson's Disease Employing cDNA Microarray
Recently, we reported specific brain gene expression changes in the chronic MPTP model in the late stage of degeneration… 
Highly Cited
2000
Highly Cited
2000
The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture
The neuronal survival properties of rasagiline (R(+)-N-propargyl-l-aminoindane mesylate or TVP-1012), a novel monoamine oxidase B… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)